GMED Stock Overview
A medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Integration With NuVasive And Rollout Of Excelsius And XR Headset Will Fuel Future Market Expansion
Globus Medical, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$71.04 |
| 52 Week High | US$94.93 |
| 52 Week Low | US$49.33 |
| Beta | 1.19 |
| 1 Month Change | -15.36% |
| 3 Month Change | -14.84% |
| 1 Year Change | 37.54% |
| 3 Year Change | 3.60% |
| 5 Year Change | 85.53% |
| Change since IPO | 426.22% |
Recent News & Updates
There May Be Reason For Hope In Globus Medical's (NYSE:GMED) Disappointing Earnings
Mar 05
Globus Medical: Some Caution After Its Deal For Nevro
Feb 16Recent updates
There May Be Reason For Hope In Globus Medical's (NYSE:GMED) Disappointing Earnings
Mar 05Globus Medical: Some Caution After Its Deal For Nevro
Feb 16Subdued Growth No Barrier To Globus Medical, Inc.'s (NYSE:GMED) Price
Jan 31Globus Medical Stock: Re-Rated After A Solid Year
Nov 18Globus Medical (NYSE:GMED) Has A Rock Solid Balance Sheet
Nov 04Globus Medical, Inc.'s (NYSE:GMED) Shareholders Might Be Looking For Exit
Oct 14Globus Medical: A Post Acquisition Analysis
Aug 26Globus Medical, Inc.'s (NYSE:GMED) Earnings Haven't Escaped The Attention Of Investors
Jun 28An Intrinsic Calculation For Globus Medical, Inc. (NYSE:GMED) Suggests It's 42% Undervalued
Apr 08Globus Medical (NYSE:GMED) Seems To Use Debt Rather Sparingly
Mar 20Globus Medical Q4: Greater Dis-Synergies Hold Back The Stock
Feb 27Globus Medical: Merger Overhang Lingering
Nov 27Globus Medical: Almost Having My Back
Sep 13Globus Medical: Slightly Too Pricey Right Now
Aug 07Globus Medical: Robotics Demand Ratcheting Higher, Reiterate Buy
Jul 18Globus Medical Q4 2022 Earnings Preview
Feb 20Globus Medical: An Impressive Long-Term Revenue Growth Play
Jan 08Shareholder Returns
| GMED | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -5.9% | -1.9% | 0.3% |
| 1Y | 37.5% | 3.8% | 9.0% |
Return vs Industry: GMED exceeded the US Medical Equipment industry which returned 3.8% over the past year.
Return vs Market: GMED exceeded the US Market which returned 9% over the past year.
Price Volatility
| GMED volatility | |
|---|---|
| GMED Average Weekly Movement | 3.7% |
| Medical Equipment Industry Average Movement | 8.8% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 17.4% |
| 10% least volatile stocks in US Market | 3.4% |
Stable Share Price: GMED has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: GMED's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 5,300 | Dan Scavilla | www.globusmedical.com |
Globus Medical, Inc., a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers musculoskeletal solutions, including spine products, such as traditional fusion implants, and treatment options for motion preservation technologies, and interventional solutions to treat vertebral compression fractures; orthopedic trauma solutions, which includes fracture plating, intramedullary nailing, and regenerative biologic products; hip and knee joint solutions, including modular hip stems and acetabular cups for total hip arthroplasty, as well as posterior stabilizing and cruciate retaining knee arthroplasty implants; and neuromonitoring services, which provides onsite and remote monitoring of the neurological systems of patients undergoing spinal and brain-related surgeries. The company also offers enabling technologies, such as imaging, navigation, and robotics (INR) solutions for assisted surgery, which includes the ExcelsiusGPS platform, a robotic guidance and navigation system for minimally invasive and open procedures with screw and interbody spacer placement applications; Surgimap, a surgical planning software platform; Excelsius3D, a platform combined with ExcelsiusGPS that provides an intraoperative, image-guided robotic navigation solution; ExcelsiusHub, which provides real-time patient array monitoring, tissue sparing drills, and registration flexibility; and ExcelsiusFlex, a total knee arthroplasty robotic solution.
Globus Medical, Inc. Fundamentals Summary
| GMED fundamental statistics | |
|---|---|
| Market cap | US$9.77b |
| Earnings (TTM) | US$102.98m |
| Revenue (TTM) | US$2.52b |
94.9x
P/E Ratio3.9x
P/S RatioIs GMED overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GMED income statement (TTM) | |
|---|---|
| Revenue | US$2.52b |
| Cost of Revenue | US$819.88m |
| Gross Profit | US$1.70b |
| Other Expenses | US$1.60b |
| Earnings | US$102.98m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.75 |
| Gross Margin | 67.46% |
| Net Profit Margin | 4.09% |
| Debt/Equity Ratio | 10.6% |
How did GMED perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/03/17 08:55 |
| End of Day Share Price | 2025/03/14 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Globus Medical, Inc. is covered by 26 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ishan Majumdar | Baptista Research |
| Matt Miksic | Barclays |
| Craig Bijou | BofA Global Research |